

A randomized, double – blind, parallel-group phase III trial investigating the glycemic efficacy and safety profile of fixed – dose combination Dapagliflozin and Linagliptin over Linagliptin monotherapy in patients with inadequately controlled type 2 diabetes with Metformin

Aditi Jain¹; Dr. Abhay Vispute²; Dr. Amol Dange³; Dr. Arindam Naskar⁴; Dr. Asish Mondal⁵; Dr. B. Vivekanand⁶; Dr. Balram Sharma⁷; Dr. Deepak Varade⁸; Dr. Dhairawat Shukla⁹; Dr. Girish Bhatia¹⁰; Dr. Harshal Chaudhari¹¹; Dr. K. Ram Babu¹²; Dr. Onkar Gavali¹³; Dr. Sanket Sorate¹⁴; Dr. Shaishav Bhanushali¹⁵; Dr. Vaibhav Kothari¹⁶; Dr. Vipul Khandelwal¹⁷; Dr. Akhilesh Sharma¹⁸; Dr. Roshan Pawar¹⁹; Dr. Mayur Mayabhate²⁰; Dr. Vinayaka Shahavi²¹; Dr. Aashishsingh Rajput²²; Mukesh Jaiswal²³

1. Deanery of Biomedical Sciences, The University of Edinburgh
2. SRV Hospital, Mumbai, India
3. Lifepoint Multispecialty Hospital, Pune, India
4. School of Tropical Medicine, Govt of West Bengal, Kolkata, India
5. Medical College & hospital, Kolkata, India
6. Andhra medical college, Vishakhapatnam, India
7. SMS Hospital, Jaipur, India
8. Shree Ashirwaad Hospital, Mumbai, India
9. V.S. General Hospital, Ahmedabad, India
10. Medipoint Hospital, Pune, India
11. Trauma Care Hospital, Mumbai, India
12. Department of medicine, Visakha Institute of medical science, Vishakhapatnam, India
13. Lokmanya Multispecialty and Accident Hospital, Nashik, India
14. Sanjeevani Criticare and Research Center, Nashik, India
15. AIMS Hospital, Mumbai, India
16. Shushrusha Navneet Memorial Hospital, Ahmedabad, India
17. Apex Hospital Pvt. Ltd, Jaipur, India
18. Medical Department, Alkem Laboratories, Mumbai, India
19. Medical Department, Alkem Laboratories, Mumbai, India
20. Medical Department, Alkem Laboratories, Mumbai, India
21. Medical Department, Alkem Laboratories, Mumbai, India
22. Medical Department, Alkem Laboratories, Mumbai, India
23. Medical Department, Alkem Laboratories, Mumbai, India

Corresponding Author:

Aditi Jain

jainaditik@gmail.com ; a.jain-16@sms.ed.ac.uk

SUPPLEMENTARY DATA

Table S1: Sample Size and Power

Two Means – Hypothesis testing for two means	
SD in group I	1
SD in group II	1
Effect size	0.4
Alpha error (%)	5
Power (1 – beta) %	80
1 or 2 sided	2
Required sample size per group	98
Total sample size required	196
Required sample size in two groups with 15% dropout	232